Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMe2411606 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advancements and challenges in the treatment of esophageal cancer: A comprehensive review.
World J Clin Oncol
December 2024
Department of Surgery, University Hospital of Larissa, Larisa GR41334, Thessalía, Greece.
Esophageal cancer (EC) is an aggressive malignancy with a poor prognosis, ranking seventh in incidence and sixth cancer-related deaths globally. EC is classified in two main types, the esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), with ESCC being more common in Eastern Europe, South Asia, and Africa, while EAC is prevalent in Western Europe and North America. Molecular analysis identifies three subgroups of ESCC, each with distinct genetic mutations and treatment responses.
View Article and Find Full Text PDFThe HPV prevention and control program in Poland: progress and the way forward.
Acta Dermatovenerol Alp Pannonica Adriat
December 2024
Center for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
This review assesses Poland's activities in preventing and managing human papillomavirus (HPV)-related diseases, summarizing information from the 2023 HPV Prevention and Control Board meeting. Progress in primary, secondary, and tertiary prevention identifies opportunities to strengthen control of cervical cancer. Poland's national HPV vaccination program, launched in June 2023, initially achieved suboptimal coverage.
View Article and Find Full Text PDFModern rectal cancer management: A review of total neoadjuvant therapy and current practices.
Am J Surg
December 2024
Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address:
Total Neoadjuvant Therapy (TNT) is a promising strategy for treating locally advanced rectal cancer (LARC) and has started to replace the traditional neoadjuvant chemoradiotherapy (CRT). This review combines findings from pivotal studies that helped TNT to integrate into clinical practice. It emphasizes the efficacy of TNT in improving the disease-free and metastasis-free survival, pathologic complete response and, according to recent studies, a potential improvement in overall survival when compared to standard CRT.
View Article and Find Full Text PDFState of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes.
Hum Vaccin Immunother
December 2025
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in the adjuvant treatment of muscle-invasive urothelial cancer (UC). Heretofore, only the anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. In our work, we deeply analyzed the results of the three pivotal studies in view of the rapidly evolving therapeutic advanced UC's scenario.
View Article and Find Full Text PDFEuropean consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.
Eur J Cancer
November 2024
University of Perugia, Unit of Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy.
This guideline was developed in close collaboration with multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF) and the European Organization for Research and Treatment of Cancer (EORTC). Recommendations for the diagnosis and treatment of melanoma were developed on the basis of systematic literature research and consensus conferences. Cutaneous melanoma (CM) is the most dangerous form of skin tumor and accounts for 90 % of skin cancer mortality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!